Onyia Jude 4

4 · NEUROCRINE BIOSCIENCES INC · Filed May 29, 2026

AI-generated summary of this filing

Updated May 29, 2026

Neurocrine (NBIX) CSO Onyia Jude Exercises Options, Sells 11,000 Shares

What Happened

Onyia Jude, Chief Scientific Officer of Neurocrine Biosciences (NBIX), exercised options to acquire 11,000 shares at $84.74 per share (cost $932,140) and those 11,000 shares were sold the same day in the open market at a weighted average price of $155.53 per share (proceeds $1,710,865). The Form 4 also reports a related derivative conversion of 11,000 shares at $0 (see footnote F4 regarding the option vesting).

Key Details

Transaction date: May 27, 2026; Form 4 filed May 29, 2026 (appears timely).
Exercise: 11,000 shares acquired @ $84.74 (total $932,140).
Sale: 11,000 shares disposed @ weighted avg $155.53 (total proceeds $1,710,865); sale prices ranged $154.47–$156.74 (F3).
Additional derivative line: 11,000 shares reported as a conversion/disposition at $0 (derivative reporting; see F4 for vesting schedule).
Sale execution: brokered under a Rule 10b5-1 trading plan adopted Feb 25, 2026; plan cannot be amended per issuer policy (F2).
Footnote: filing notes 176 shares purchased Feb 27, 2026 via the company ESPP (F1).
Shares owned after the reported transactions are not specified in the provided extract.

Context

The exercise and same-day sale is consistent with an option exercise followed by an immediate market disposition (commonly used to cover exercise cost or realize gains). Footnote F4 explains the options’ vesting schedule; F2 confirms the sale was executed under a pre-established 10b5-1 plan. This is a routine insider sale following option exercise and should be read as a disclosure of transaction—not as explicit commentary on company prospects.

Form 4

Period: 2026-05-27

Chief Scientific Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-05-27$84.74/sh+11,000$932,140→ 36,846 total
Sale
Common Stock
[F2][F3]
2026-05-27$155.53/sh−11,000$1,710,865→ 25,846 total
Exercise/Conversion
Non-Qualified Stock Option
[F4]
2026-05-27−11,000→ 24,268 total
Exercise: $84.74Exp: 2031-11-29→ Common Stock (11,000 underlying)

Footnotes (4)

[F1]Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
[F2]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
[F3]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $154.47 to $156.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F4]Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.

Signature

/s/ Darin Lippoldt, Attorney-in-Fact|2026-05-28

1 file